Products

LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
OnQ Neuro
CorTechs Labs
Neurology AI
OnQ Neuro by CorTechs Labs is an FDA-cleared, AI-powered software for automated segmentation and volumetric quantification of brain tumors on MRI, supporting clinical analysis and interpretation.
NeuroQuant
CorTechs Labs
Neurology AI
NeuroQuant by CorTechs Labs is an FDA-cleared, AI-powered software for automated brain MRI segmentation and volumetric analysis, aiding in the diagnosis and monitoring of neurodegenerative diseases, brain trauma, and tumors.

See all 3 products →

About CorTechs Labs

CorTechs Labs, now operating as Cortechs.ai, is a leading healthcare AI company specializing in advanced medical imaging analysis. Their core mission is to empower physicians and clinicians with sophisticated AI solutions to enhance the detection, diagnosis, and treatment of various neurological and oncological diseases. They achieve this by integrating state-of-the-art medical imaging with machine learning and clinical data, developing tools designed to improve patient outcomes and streamline clinical workflows.

The company’s flagship product, NeuroQuant®, provides automated segmentation and volumetric analysis from brain MRI scans. This technology offers quantitative measurements of brain structures, comparing them to a unique normative database adjusted for age, sex, and intracranial volume. This objective data is crucial for assessing and monitoring neurodegenerative conditions such as Alzheimer’s disease, multiple sclerosis, epilepsy, and brain trauma. Additionally, Cortechs.ai offers OnQ™ Prostate, an AI-powered solution that leverages Restriction Spectrum Imaging (RSI) to improve the detection of clinically significant prostate cancer.

Cortechs.ai’s FDA-cleared products are designed to replace time-consuming manual processes with efficient, automated analysis, thereby accelerating diagnostic pathways and supporting comprehensive treatment follow-up. Their precision volumetric analysis technology is currently utilized in over 1,400 hospitals and imaging centers globally, demonstrating a significant impact on clinical practice by providing objective, quantitative insights to healthcare professionals.

Focus Areas

Neuroimaging Oncology Neurodegenerative Diseases Alzheimer's Disease Multiple Sclerosis Epilepsy Traumatic Brain Injury Prostate Cancer Brain Tumors Quantitative Imaging AI-Powered Diagnostics Clinical Decision Support Machine Learning Deep Learning

Business Intelligence

Key InvestorsGenting Berhad (via Dragasac Limited), VILAS Ventures, Paul J. Mirabella
PartnershipsNovartis, Subtle, Imaging Biometrics, GE Healthcare, Human Longevity, Siemens Healthineers, Philips Healthcare, deepc
AcquisitionsHealthLytix (merged 2020), ZepMed (acquired IP 2025)
TechnologyCloud-based AI software, Deep Learning, Machine Learning, Restriction Spectrum Imaging (RSI-MRI+), Dynamic Atlas™ technology
FDA Clearances5 cleared products (estimated)

What Physicians Need to Know

Neuroimaging & Neurodegenerative Diseases
CorTechs Labs (now Cortechs.ai) offers a comprehensive suite of AI-powered software for quantitative analysis of brain images. Key products like NeuroQuantu00ae provide automated segmentation and volumetric analysis of brain structures, comparing them to a normative database adjusted for age, sex, and intracranial volume. This aids in the early detection, diagnosis, and monitoring of neurodegenerative conditions such as Alzheimer's Disease, Multiple Sclerosis (MS), Epilepsy, and Traumatic Brain Injury (TBI). NeuroQuantu00ae MS specifically visualizes and quantifies lesions and their volume changes. PETQuantu2122 is a research tool for quantifying PET tracer bindings in brain structures for conditions like frontotemporal dementia and Alzheimer's. NeuroQuant CT offers automated CT alignment for fast, accurate diagnosis.
Oncology
The company has expanded its focus into oncology with solutions like OnQu2122 Prostate, which optimizes prostate MRI for advanced clinical insights and improved prostate cancer detection and diagnosis using Restriction Spectrum Imaging (RSI-MRI+). NeuroQuantu00ae Brain Tumor provides pre- and post-operative 3D volume analysis of brain tumors, including automated segmentation and volumetric reporting for high-grade gliomas, brain metastases, and meningiomas.
AI-Powered Diagnostics & Quantitative Imaging
Cortechs.ai leverages cutting-edge AI, machine learning, and deep learning to provide automated, objective, and reproducible quantitative imaging biomarkers. Their software replaces time-consuming manual processes, offering consistent and accurate measurements of brain structures and lesions. This technology is designed to streamline diagnostic workflows and improve the accuracy of neurological and oncological assessments.
Clinical Decision Support
Their solutions are designed to serve as powerful clinical decision support tools, empowering physicians with objective, quantitative data to aid in faster, more accurate diagnoses, effective treatment planning, and monitoring of disease progression. The reports are tailored to specific diseases and provide insights that complement clinical impressions.
Physician Tip

For physicians, Cortechs.ai's solutions offer several distinct advantages. They provide objective, quantitative data from MRI and CT scans, reducing the subjectivity and variability inherent in manual interpretations. This leads to increased diagnostic confidence and allows for earlier detection and more precise monitoring of disease progression in conditions like Alzheimer's, MS, and brain tumors. The automated nature of the software significantly streamlines workflow, freeing up valuable physician time to focus on patient care rather than laborious image analysis. Furthermore, the ability to track changes over time with longitudinal reports helps in assessing treatment effectiveness and making data-driven adjustments to patient management plans. The FDA clearance and CPT codes associated with their products also provide regulatory confidence and facilitate reimbursement.

Cortechs.ai's software, including NeuroQuantu00ae, LesionQuantu2122, PETQuantu2122, and OnQu2122 Prostate, is designed for seamless integration with existing PACS systems and various MRI scanners (GE, Philips, Siemens, Canon, Hitachi). They also partner with platforms like deepcOSu00ae and Siemens Healthineers Digital Marketplace to expand global access and integrate their AI-enabled analytics directly into imaging workflows, enhancing interoperability across departments like radiology, neurosurgery, and radiation oncology.

Products by CorTechs Labs

3 products in the directory

LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
OnQ Neuro
CorTechs Labs
Neurology AI
OnQ Neuro by CorTechs Labs is an FDA-cleared, AI-powered software for automated segmentation and volumetric quantification of brain tumors on MRI, supporting clinical analysis and interpretation.
NeuroQuant
CorTechs Labs
Neurology AI
NeuroQuant by CorTechs Labs is an FDA-cleared, AI-powered software for automated brain MRI segmentation and volumetric analysis, aiding in the diagnosis and monitoring of neurodegenerative diseases, brain trauma, and tumors.

Reviews & Opinions

No web reviews on file yet for CorTechs Labs. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about CorTechs Labs.

Loading videos...

Videos load interactively. If none appear, search YouTube for CorTechs Labs →

View all on YouTube

Press & Coverage

Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration
Viz.ai announced a collaboration with Cortechs.ai to integrate NeuroQuant and NeuroQuant MS into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease.
2026-07
Imaging Technology News
Cortechs.ai, Microsoft Collaborate on AI-Powered Imaging for Radiology Workflows
Cortechs.ai announced a strategic collaboration with Microsoft to integrate advanced imaging biomarkers and AI-driven insights into clinical radiology workflows, aiming to enhance diagnostic precision and streamline reporting.
2026-06
PR Newswire
Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuantu00ae Technologies
Cortechs.ai announced a strategic partnership with Siemens Healthineers to integrate and distribute its FDA-cleared NeuroQuantu00ae Lesion Surveillance through the Siemens Healthineers Digital Marketplace. This collaboration aims to accelerate the worldwide adoption of quantitative brain imaging.
2026-03
Cortechs.ai
Cortechs.ai Receives Health Canada Approval to Expand Sales of AI-Powered Imaging Solutions in North America
Cortechs.ai announced it has received approval from Health Canada for the sale of its innovative suite of imaging solutions, marking a significant expansion into the Canadian healthcare market.
2025-04
Applied Radiology
Cortechs.ai Expands NeuroQuantu00ae to Revolutionize Brain Tumor Imaging with AI
Cortechs.ai announced a major enhancement to its FDA-cleared NeuroQuantu00ae Brain Tumor software, introducing fully automated segmentation and volumetric reporting for brain metastases and meningiomas.
2025-07
NeurologyLive
FDA Clears Cortechs.ai's NeuroQuant 5.0 Software for Quantification and Segmentation of ARIA-E and ARIA-H
Cortechs.ai has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NeuroQuant 5.0 software, which allows radiologists to improve segmentation for amyloid-related imaging abnormalities (ARIA) in patients undergoing anti-amyloid treatment for Alzheimer's disease.
2024-09
Applied Radiology
Cortechs.AI Receives NIH Grant to Develop ARIA Detection Software
Cortechs.ai announced it has received a three-year, multimillion-dollar NIH grant to support the development of additional analysis software to automatically detect and quantify Amyloid Related Imaging Abnormalities (ARIA) in Alzheimer's disease patients.
2024-08
Cortechs.ai
Cortechs.ai awarded million dollar NIH grant
Cortechs.ai received a $1.35 million, 2.5-year grant from the National Institutes of Health (NIH) to advance Alzheimer's Disease diagnosis by quantifying microstructural changes using Restriction Spectrum Imaging.
2022-08

Frequently Asked Questions

CorTechs Labs offers a suite of AI-powered neuroimaging solutions, including NeuroQuantu00ae, NeuroQuantu00ae MS, NeuroQuantu00ae Brain Tumor, NeuroQuant CT, NeuroQuant PET, and OnQu2122 Prostate. These products provide quantitative analysis of brain structures and prostate MRI, aiding in the assessment of neurodegenerative diseases like Alzheimer's, Multiple Sclerosis, Epilepsy, and Traumatic Brain Injury, as well as brain tumors and prostate cancer.
CorTechs Labs' solutions provide objective, volumetric data and color-coded analysis of brain structures, enhancing diagnostic accuracy and reducing variability for neurodegenerative diseases. For oncology, products like NeuroQuantu00ae Brain Tumor and OnQu2122 Prostate automate segmentation and volumetric analysis of tumors, supporting precision-based longitudinal monitoring and treatment planning.
CorTechs Labs' products, including NeuroQuantu00ae, are FDA 510(k) cleared medical device software, with NeuroQuant 5.0 specifically cleared for advanced segmentation and quantification of ARIA lesions. The company is also fully compliant with HIPAA, ensuring secure and private handling of protected health information in its cloud-based processing systems.
CorTechs Labs utilizes AI, machine learning, and deep learning to automate the segmentation, quantification, and comparison of brain and prostate structures from medical images. This advanced technology enables precise volumetric analysis, helps discriminate tumor from non-tumor tissue, and supports the development of quantitative imaging biomarkers for improved diagnosis and treatment response prediction.
CorTechs Labs provides comprehensive support to healthcare providers through various channels, including a dedicated support page for submitting tickets and accessing resources. They also offer training videos and information on Neuro and Prostate CPT codes to assist with billing and integration into clinical workflows.
CorTechs Labs actively pursues strategic partnerships with major healthcare technology companies like Philips and Siemens Healthineers to expand the global reach and integration of its solutions. These collaborations aim to seamlessly deploy advanced imaging applications into clinical workflows, improving diagnostic precision and enhancing patient care worldwide.
While specific pricing details are not publicly disclosed, CorTechs Labs' solutions are typically offered through models that provide a cost-effective way to quantify brain structures. Pricing is generally structured to accommodate healthcare institutions and may involve subscription-based access or per-scan fees, requiring direct consultation for detailed quotes.
CorTechs Labs demonstrates strong financial stability, having secured multiple funding rounds, including an oversubscribed Series C round led by VILAS Ventures with participation from existing investor Genting Berhad. The company has shown consistent growth, expanding its commercial footprint and deepening engagement with major healthcare organizations globally.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.